FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/06/2024
Voltar para busca
Dado oficial do USPTO
PARMODIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
17/06/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
17/02/2023
Data de registro
06/02/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/02/2024
Última transação
06/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
JP
Examinador
MORRIS, KRISTINA KLOIBER
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
KOWA COMPANY, LTD.
Representantes
Erica Halstead Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationspharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseasespharmaceutical preparations for treatment of fatty liver and steatohepatitispharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorderspharmaceutical preparations for the treatment of digestive system diseasepharmaceutical preparations for the treatment of primary biliary cirrhosispharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosispharmaceutical preparations for the treatment of liver diseasepharmaceutical preparations for the treatment of metabolic diseasepharmaceutical preparations for the prevention and treatment of disorders of the metabolic systemanalgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous systemperipheral nervous systemsensory organsthe circulatory systemrespiratory systemthe digestive system; pharmaceutical substances for the treatment of dermatological diseasesallergies and urogenital or anal conditions; veterinary preparationsveterinary preparations for the treatment of diseases of the circulatory system and diabetes-related diseasesveterinary preparations for treatment of fatty liver and steatohepatitisveterinary preparations for the treatment of cardiovascular disorders and metabolic disordersveterinary preparations for the treatment of digestive system diseaseveterinary preparations for the treatment of primary biliary cirrhosisveterinary preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosisveterinary preparations for the treatment of liver diseaseveterinary preparations for the treatment of metabolic diseaseveterinary preparations for the prevention and treatment of disorders of the metabolic systemanalgesics; veterinary pharmaceutical and biological preparations for the treatment of diseases of the central nervous systemperipheral nervous systemsensory organsthe circulatory systemrespiratory systemthe digestive system; veterinary pharmaceutical substances for the treatment of dermatological diseasesallergies and urogenital or anal conditions; sanitary preparations for medical use; anti-inflammatory agentstopical preparations in the form of gels and salvesadhesive skin patchesliquid formulationscream and spraysall for relieving pain
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/05/2024
FIMP
FINAL DISPOSITION PROCESSED
13/05/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/05/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2024
GPNX
NOTIFICATION PROCESSED BY IB
27/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/11/2023
PUBO
PUBLISHED FOR OPPOSITION
21/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/11/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/10/2023
ATRV
ATTORNEY REVIEW COMPLETED
02/09/2023
RFNT
REFUSAL PROCESSED BY IB
14/08/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
24/07/2023
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
24/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/07/2023
RFRR
REFUSAL PROCESSED BY MPU
14/07/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
12/07/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/06/2023
CNRT
NON-FINAL ACTION WRITTEN
07/06/2023
DOCK
ASSIGNED TO EXAMINER
25/05/2023
MAFR
APPLICATION FILING RECEIPT MAILED
23/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/05/2023
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
18/05/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PARMODIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.